Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
varsetatug masetecan · 1 trial · 1 indication
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
PFS defined as the time from participant allocation to a trial intervention to the first documentation of objective disease progression, as determined by BICR according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| varsetatug masetecan + bevacizumab + 5-FU + leucovorin | EXPERIMENTAL | - |
| varsetatug masetecan + bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| varsetatug masetecan | DRUG | Investigational Product |
| bevacizumab + 5-FU + leucovorin | DRUG | IV infusion |
| bevacizumab | DRUG | IV infusion |
Inclusion Criteria: * Histologically or cytologically documented unresectable metastatic CRC * Documented progression during or following exactly one prior regimen of systemic therapy with or without targeted therapy for metastatic CRC * Measurable disease per RECIST v1.1 * Eastern Cooperative Onco...
Top 20 of 79 competitors